Cancer Clinical Trial
— ACCESSOfficial title:
Activating Cancer Communities Through an Exercise Strategy for Survivors (ACCESS)
Cancer continues to have the dubious honor of being the leading cause of premature mortality in Canada. The good news is, advances in early detection and cancer treatments are extending the lives of those diagnosed with the disease. However, as more people are living longer, the impact of the therapies used to treat the disease are becoming increasingly apparent. Ranging from the physiological to psychological, cancer survivors are often confronted with substantial, disabling, and life-threatening consequences. The benefits of physical activity (all movement) and exercise more specifically have long been established as a means of prevention and treatment of chronic disease. Several recent reviews and meta-analyses have demonstrated that exercise is a safe and effective means of preventing and improving a multitude of physical and psychological treatment and disease-related sequelae across the cancer trajectory. For example, we know that cancer survivors who exercise not only have a reduced risk of disease recurrence and cancer mortality, but also have reduced acute/late effects of their cancer and/or its treatment such as anxiety, depression, and cancer-related pain. Regrettably, despite our substantial knowledge base, the majority of cancer survivors are not sufficiently active to realize these benefits over the long-term. Moreover, even with the development of evidence-based guidelines, exercise has not yet been widely implemented as a standard of care in the oncology setting largely due to a lack of resources, exercise expertise, and awareness of benefits. Continuing to provide cancer care with little guidance and understanding of the benefits of exercise places cancer survivors at an increased risk for recurrence, late effects, and/or onset of additional co-morbidities, and premature mortality. Therefore, it is important to consider best practices that will optimize and improve quality of survival. Building on the ongoing work of our Alberta-based colleagues and the Alberta Cancer Exercise (ACE) Program (an evidence-based clinic-to-community cancer exercise model), Activating Cancer Communities through an Exercise Strategy for Survivors (ACCESS) is designed to bridge the gap between research and practice and in doing so, lessen the impact of a cancer diagnosis and its treatment(s) on the physical and psychological well-being of cancer survivors.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have a diagnosis of cancer; - Be 18+ years; - Be pre-treatment, receiving active treatment, or have received cancer treatment within the past 5 years or have a late presenting/ongoing side-effects related to the cancer diagnosis; - Be able to participate in mild levels of physical activity (at a minimum); - Be willing to attend a 12-week exercise program in Halifax; - Be able to provide informed written consent in English. Exclusion Criteria: - Less than 18 years of age. |
Country | Name | City | State |
---|---|---|---|
Canada | QEII Health Sciences Centre (Dickson Bldg) | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Nova Scotia Health Authority |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physiological Outcome - resting heart rate | Seated resting heart rate will be measured in beats per minute. | 12 weeks | |
Primary | Physiological outcome - blood pressure | Seated systolic and diastolic blood pressure will be measured in mm of Hg | 12 weeks | |
Primary | Physiological outcome - 6 minute walk test (6MWT) | The total distance walked in 6 minutes will be measured in meters | 12 weeks | |
Primary | Physiological Outcome - handgrip | Handgrip will be measured in both the left and right hand. Two trials will be conducted on each side and the highest score will be used. Handgrip is measured in kg. | 12 weeks | |
Primary | Physiological outcome - timed sit-to-stand | Time, is seconds, required to move from a seated to a standing position will be recorded. | 12 weeks | |
Primary | Physiological Outcome - one legged stance/balance | Participants will be asked to stand on one leg with no support for as long as they can up to a maximum of 45 seconds. Trials will be conducted on the right and left side and time will be recorded in seconds. | 12 weeks | |
Primary | Physiological Outcome - sit-and-reach | Hamstring flexibility will be measured in centimeters. | 12 weeks | |
Primary | Physiological Outcome - shoulder flexibility | Shoulder flexibility will be measured in degrees | 12 weeks | |
Primary | Daily steps | Total number of daily steps will be recorded using a pedometer. | 12 weeks | |
Primary | Functional Assessment of Cancer therapy General (FACT-G) | The FACT-G is used to assess quality of life. It is a 27 item compilation of questions dived in four primary quality of life domains: 1) physical well-being; 2) social/family well-being; 3) emotional well-being; and 4) functional well-being. | 12 weeks | |
Primary | Physical Activity Behaviour | The Godin Leisure Time Exercise Questionnaire will be used to assess physical activity and sedentary behaviour. | 12 weeks | |
Primary | Sleep Quality | Sleep quality will be assessed using the Pittsburgh sleep quality index. | 12 weeks | |
Primary | Depression Anxiety Stress Scales (DASS) | The depression anxiety stress scales consists of a list of 42 symptoms associated with depression, anxiety or stress. The participant is asked score the severity of the symptom over the past week on a 4 point scale. | 12 weeks | |
Primary | Fatigue | The functional assessment of chronic illness therapy-fatigue (FACIT-F), which is a 13-item scale, will be used to assess participant levels of fatigue. | 12-weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|